Piper Sandler restated their overweight rating on shares of InspireMD (NYSE:NSPR – Free Report) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $4.50 target price on the stock.
Separately, StockNews.com began coverage on InspireMD in a report on Sunday, September 15th. They set a sell rating on the stock.
Read Our Latest Stock Report on InspireMD
InspireMD Price Performance
InspireMD (NYSE:NSPR – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter last year, the business posted ($0.24) earnings per share. On average, equities research analysts predict that InspireMD will post -0.82 EPS for the current fiscal year.
Hedge Funds Weigh In On InspireMD
An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. bought a new position in InspireMD, Inc. (NYSE:NSPR – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc. owned approximately 0.13% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.
InspireMD Company Profile
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Featured Articles
- Five stocks we like better than InspireMD
- Retail Stocks Investing, Explained
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What is a Stock Market Index and How Do You Use Them?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Canadian Penny Stocks: Can They Make You Rich?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.